Lung cancer: cross-border access to US specialty therapies for international patients
Oncology · specialty and rare-disease access
ICD-10: C34
About lung cancer
Lung cancer, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), has been transformed in modern oncology by biomarker-directed targeted therapy and checkpoint immunotherapy. The specialty treatment toolkit now includes EGFR-directed Tagrisso (osimertinib), ALK-directed Lorbrena (lorlatinib), KRAS-G12C-directed Krazati (adagrasib), MET-directed Tabrecta (capmatinib), and anti-PD-1 or anti-PD-L1 checkpoint immunotherapies (Keytruda, Opdivo, Tecentriq).
Why specialty drugs for lung cancer are hard to access internationally
The newer biomarker-targeted and immunotherapy agents have narrower global registration and inconsistent reimbursement coverage outside the United States. Patients in countries where their prescribed treatment is not registered or not covered often face long delays or out-of-pocket gaps. Comprehensive molecular profiling is also unevenly available, which can leave patients without the matched therapy that their tumour biology calls for.
Access to specialty treatment
Patients with lung cancer who live in countries where their prescribed treatment is not registered or is not covered by insurance can consider Named Patient Program (NPP) access. Reserve Meds coordinates this pathway: we work with your treating physician, support destination-country documentation (for example CDSCO in India, MoHAP in the UAE, SFDA in Saudi Arabia), and source the medicine from DSCSA-compliant US wholesalers.
Cross-border pathways used for lung cancer
Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:
What your physician needs to know
- Availability of comprehensive molecular profiling (EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, HER2).
- PD-L1 expression level and tumour mutational burden.
- Whether targeted therapy is appropriate before immunotherapy (mutation-driven sequencing).
- Which documents the destination country requires for precision-oncology drugs.
Where Reserve Meds fits in
Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For lung cancer, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.
We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.
Start a request
Request a drug for lung cancer
Reserved for you.